ONE-WAY ANOVA ONE-WAY ANOVA ONE-WAY ANOVA ONE-WAY ANOVA
Parameter Treatment Treatment Treatment Treatment
Stepping test - acute doxycycline (Fig. 1-C)
F (4, 43) = 6.51 P < 0.001 F (4, 43) = 6.51 P < 0.001 F (4, 43) = 6.51 P < 0.001 F (4, 43) = 6.51 P < 0.001
Time of immobility in the open field - acute doxycycline (Fig. 1-D)
F (4, 43) = 11.92 P < 0.0001 F (4, 43) = 11.92 P < 0.0001 F (4, 43) = 11.92 P < 0.0001 F (4, 43) = 11.92 P < 0.0001
Distance travelled in the open field - acute doxycycline (Supplementary table 1)
F (4, 43) = 39.02 P < 0.0001 F (4, 43) = 39.02 P < 0.0001 F (4, 43) = 39.02 P < 0.0001 F (4, 43) = 39.02 P < 0.0001
Time of immobility in the open field - acute COL-3 (Supplementary table 1)
F (1, 16) = 17.278 P < 0.001 F (1, 16) = 17.278 P < 0.001 F (1, 16) = 17.278 P < 0.001 F (1, 16) = 17.278 P < 0.001
Distance travelled in the open field – acute COL-3 (Supplementary table 1)
F (1, 18) = 18.32 P < 0.001 F (1, 18) = 18.32 P < 0.001 F (1, 18) = 18.32 P < 0.001 F (1, 18) = 18.32 P < 0.001
ROS - acute doxycycline (Fig. 3-G) F (2, 15) = 50.46 P < 0.0001 F (2, 15) = 50.46 P < 0.0001 F (2, 15) = 50.46 P < 0.0001 F (2, 15) = 50.46 P < 0.0001
Gelatinolytic activity - acute doxycycline (Fig. 3-I)
F (2, 16) = 153.4 P < 0.0001 F (2, 16) = 153.4 P < 0.0001 F (2, 16) = 153.4 P < 0.0001 F (2, 16) = 153.4 P < 0.0001
MMP-3 - acute doxycycline (Fig. 3-K)
F (2, 16) = 584.0 P < 0.0001 F (2, 16) = 584.0 P < 0.0001 F (2, 16) = 584.0 P < 0.0001 F (2, 16) = 584.0 P < 0.0001
ROS - chronic doxycycline (Fig. 4-I) F (2, 14) = 611.7 P < 0.0001 F (2, 14) = 611.7 P < 0.0001 F (2, 14) = 611.7 P < 0.0001 F (2, 14) = 611.7 P < 0.0001
Gelatinolytic activity - chronic doxycycline (Fig. 4-K)
F (2, 16) = 100.3 P < 0.0001 F (2, 16) = 100.3 P < 0.0001 F (2, 16) = 100.3 P < 0.0001 F (2, 16) = 100.3 P < 0.0001
MMP-2 - acute doxycycline (Supplementary Fig. 4-A)
F (2, 15) = 0.1948 P = 0.82 F (2, 15) = 0.1948 P = 0.82 F (2, 15) = 0.1948 P = 0.82 F (2, 15) = 0.1948 P = 0.82
MMP-9 - acute doxycycline (Supplementary Fig. 4-B)
F (2, 15) = 6.408 P < 0.001 F (2, 15) = 6.408 P < 0.001 F (2, 15) = 6.408 P < 0.001 F (2, 15) = 6.408 P < 0.001
MMP-2 chronic doxycycline (Supplementary Fig. 4-C)
F (2, 15) = 9.828 P < 0.01 F (2, 15) = 9.828 P < 0.01 F (2, 15) = 9.828 P < 0.01 F (2, 15) = 9.828 P < 0.01
MMP-9 chronic doxycycline (Supplementary Fig. 4-D)
F (2, 15) = 49.83 P < 0.0001 F (2, 15) = 49.83 P < 0.0001 F (2, 15) = 49.83 P < 0.0001 F (2, 15) = 49.83 P < 0.0001
RM ONE-WAY ANOVA RM ONE-WAY ANOVA RM ONE-WAY ANOVA RM ONE-WAY ANOVA
Parameter Treatment Treatment Treatment Treatment
AIMs - acute doxycycline (Fig. 1-A) F (3, 30) = 11.07 P < 0.0001 F (3, 30) = 11.07 P < 0.0001 F (3, 30) = 11.07 P < 0.0001 F (3, 30) = 11.07 P < 0.0001
AIMs - acute COL-3 (Fig. 5-A) F (1,549, 9,294) = 23.87 P < 0.001 F (1,549, 9,294) = 23.87 P < 0.001 F (1,549, 9,294) = 23.87 P < 0.001 F (1,549, 9,294) = 23.87 P < 0.001
TWO-WAY ANOVA TWO-WAY ANOVA TWO-WAY ANOVA TWO-WAY ANOVA
Parameter L-DOPA Treatment Doxycycline Treatment Doxycycline Treatment Interaction
FOS-B – acute doxycycline (Fig. 2-C)
F (1, 16) = 54.06 P < 0.0001 F (1, 16) = 2.832 P = 0.1118 F (1, 16) = 2.832 P = 0.1118 F (1, 16) = 6.609 P < 0.05
COX-2 – acute doxycycline (Fig. 2-F)
F (1, 19) = 13.33 P < 0.01 F (1, 19) = 0.5967 P = 0.45 F (1, 19) = 0.5967 P = 0.45 F (1, 19) = 6.744 P < 0.05
OX-42 – acute doxycycline (Fig. 2-L)
F (1, 22) = 106.5 P < 0.0001 F (1, 22) = 14.63 P < 0.001 F (1, 22) = 14.63 P < 0.001 F (1, 22) = 7.140 P < 0.05
GFAP – acute doxycycline (Fig. 2-I) F (1, 22) = 98.57 P < 0.0001 F (1, 22) = 44.26 P < 0.0001 F (1, 22) = 44.26 P < 0.0001 F (1, 22) = 8.810 P < 0.01
Distance travelled in the open field - chronic doxycycline (Supplementary table 1)
F (1, 21) = 21.11 P < 0.01 F (1, 21) = 0.153 P = 0.89 F (1, 21) = 0.153 P = 0.89 F (1, 21) = 0.07 P = 0.79
Time of immobility in the open field - chronic doxycycline (Supplementary table 1)
F (1, 21) = 39.76 P < 0.0001 F (1, 21) = 2.500 P = 0.13 F (1, 21) = 2.500 P = 0.13 F (1, 21) = 1.563 P = 0.22
RM TWO-WAY ANOVA RM TWO-WAY ANOVA RM TWO-WAY ANOVA RM TWO-WAY ANOVA
Parameter Treatment Time Time Interaction
Time course of AIMs - acute doxycycline (Fig. 1-B)
F (1, 10) = 15.17 P < 0.0001 F (9, 90) = 23.17 P = 0.003 F (9, 90) = 23.17 P = 0.003 F (9, 90) = 9.42 P < 0.0001
AIMs - chronic doxycycline (Fig. 4-A)
F (1, 30) = 492 P < 0.0001 F (2, 32) = 22.92 P < 0.0001 F (2, 32) = 22.92 P < 0.0001 F (2, 30) = 23.31 P < 0.0001
Time course of AIMs - chronic doxycycline (Fig. 4-B)
F (1, 10) = 746.3 P < 0.0001 F (9, 90) = 68.03 P < 0.0001 F (9, 90) = 68.03 P < 0.0001 F (9, 90) = 63.26 P < 0.0001
Time course of AIMs - acute COL-3 (Fig. 5-B)
F (1, 63) = 36.19 P < 0.0001 F (8, 63) = 13.01 P < 0.0001 F (8, 63) = 13.01 P < 0.0001 F (8, 63) = 2.974 P = 0.0069
PAIRED T-TEST PAIRED T-TEST PAIRED T-TEST PAIRED T-TEST
Parameter
Effect Effect Effect Effect
Axial, Limb and Orofacial measures AIMs – acute doxycycline (Supplementary Fig. 2-A, -B and -C)
Axial:
T=1.401
P<0.05
Axial:
T=1.401
P<0.05
Limb:
T=4.422
P=0.0013
Orofacial:
T=2.767
P=0.0199
Axial, Limb and Orofacial measures AIMs – chronic doxycycline (Supplementary Fig. 2-D, -E and -F)
Axial:
T=3.590
P<0.05
Axial:
T=3.590
P<0.05
Limb:
T=4.216
P=0.00012
Orofacial:
T=4.657
P=0.0023
Axial, Limb and Orofacial measures AIMs – COL-3 (Supplementary Fig. 2-G, -H and -I)
Axial:
T=3.738
P=0.0022
Axial:
T=3.738
P=0.0022
Limb:
T=5.259
P=0.0001
Orofacial:
T=2.214
P<0.05
b Parametric statistical analyses carried out to calculate measures of spread from data observed in this study. ANOVA, analysis of variance; COL-3, CMT-3,6-demethyl-6-deoxy-4-de[dimethylamino]-tetracycline formerly known as Incyclinide; COX-2, Cyclooxygenase-2; F, F statistic; FOS-B, protein FOS-B; GFAP, Glial fibrillary acidic protein; MMP, Matrix metalloproteinase; OX-42, CD11b/c equivalent protein of microglia; P, P value; RM, repeated measures; ROS, reactive oxygen species; t, t value in the student’s t-test. b Parametric statistical analyses carried out to calculate measures of spread from data observed in this study. ANOVA, analysis of variance; COL-3, CMT-3,6-demethyl-6-deoxy-4-de[dimethylamino]-tetracycline formerly known as Incyclinide; COX-2, Cyclooxygenase-2; F, F statistic; FOS-B, protein FOS-B; GFAP, Glial fibrillary acidic protein; MMP, Matrix metalloproteinase; OX-42, CD11b/c equivalent protein of microglia; P, P value; RM, repeated measures; ROS, reactive oxygen species; t, t value in the student’s t-test. b Parametric statistical analyses carried out to calculate measures of spread from data observed in this study. ANOVA, analysis of variance; COL-3, CMT-3,6-demethyl-6-deoxy-4-de[dimethylamino]-tetracycline formerly known as Incyclinide; COX-2, Cyclooxygenase-2; F, F statistic; FOS-B, protein FOS-B; GFAP, Glial fibrillary acidic protein; MMP, Matrix metalloproteinase; OX-42, CD11b/c equivalent protein of microglia; P, P value; RM, repeated measures; ROS, reactive oxygen species; t, t value in the student’s t-test. b Parametric statistical analyses carried out to calculate measures of spread from data observed in this study. ANOVA, analysis of variance; COL-3, CMT-3,6-demethyl-6-deoxy-4-de[dimethylamino]-tetracycline formerly known as Incyclinide; COX-2, Cyclooxygenase-2; F, F statistic; FOS-B, protein FOS-B; GFAP, Glial fibrillary acidic protein; MMP, Matrix metalloproteinase; OX-42, CD11b/c equivalent protein of microglia; P, P value; RM, repeated measures; ROS, reactive oxygen species; t, t value in the student’s t-test. b Parametric statistical analyses carried out to calculate measures of spread from data observed in this study. ANOVA, analysis of variance; COL-3, CMT-3,6-demethyl-6-deoxy-4-de[dimethylamino]-tetracycline formerly known as Incyclinide; COX-2, Cyclooxygenase-2; F, F statistic; FOS-B, protein FOS-B; GFAP, Glial fibrillary acidic protein; MMP, Matrix metalloproteinase; OX-42, CD11b/c equivalent protein of microglia; P, P value; RM, repeated measures; ROS, reactive oxygen species; t, t value in the student’s t-test.